SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as investors express significant frustration and skepticism toward the Board's decision to accept an all-cash acquisition offer, which many feel drastically undervalues the company's cash position, core drug assets, and future growth potential. The community is actively debating the merits of the deal, with some shareholders organizing to oppose the tender offer and others seeking legal avenues to challenge what they characterize as an unethical 'fire sale' by management.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is seeing intense community debate following a weak earnings report, with investors expressing frustration over the lack of capital deployment and the stock's underperformance compared to the broader market. While some shareholders are calling for dividends or aggressive buybacks to counter the stagnation, others remain focused on the company's massive cash pile as a potential defensive play during ongoing geopolitical uncertainty.

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.

LENSAR Inc

LENSAR Inc. shares are under significant pressure following the mutual termination of its merger agreement with Alcon, a decision prompted by mounting regulatory opposition from the FTC. The community is actively debating the company's standalone future, weighing concerns over operational liquidity and intense market competition against the potential durability of its recurring revenue model and ALLY system adoption.

Maulcoin

Maulcoin is trending as the community celebrates the restoration of its ticker symbol and anticipates the upcoming release of a price chart. Supporters are actively engaging in community-led growth strategies, framing the project as an honest, long-term alternative to typical pump-and-dump meme coins.

WorldFinancial

WLFI is currently facing significant volatility and intense community debate as investors react to congressional scrutiny regarding the project's foreign investment ties and its relationship with the Trump administration. While some participants view the current price action as a strategic accumulation opportunity ahead of upcoming industry forums, others express concern over token dilution, governance transparency, and the potential for the project to follow the downward trajectory of past politically-linked assets.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is gaining momentum as market participants track its role as a liquidity hub on the Base ecosystem, with investors closely watching for impact from an upcoming industry event. Community sentiment is largely focused on the potential for long-term utility-driven growth, bolstered by recent partnership announcements and the broader rotation of capital into DeFi assets.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is capturing market attention as traders position for the upcoming smart contract launch and anticipated Tier 1 exchange listings. The community remains deeply divided, with optimistic holders accumulating in anticipation of long-term infrastructure utility, while others express frustration over recent price volatility and past developmental delays.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as investors react to the company's ambitious Investor Day roadmap, which includes the unveiling of a sub-$50,000 midsize EV platform and a new robotaxi concept. While some in the community are bullish on the long-term vision and potential partnerships with Uber, others remain skeptical, focusing on the company's persistent cash burn and the long timeline to achieving positive free cash flow.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is experiencing significant community interest and high trading volumes as market participants closely watch the asset for a potential breakout above key resistance levels. Traders are actively debating whether the token is poised to repeat historical growth patterns as an alternative to other major layer-one blockchains, balancing optimism over institutional accumulation with concerns regarding market volatility.

Phillips 66 engages in the processing, transportation, storage, and marketing of fuels and other related products. The company operates through the following segments: Midstream, Chemicals, Refining, Renewable Fuels, Marketing and Specialties, and Corporate and Other. The Midstream segment provides crude oil and refined products transportation, terminal, and processing services, as well as natural gas, natural gas liquids, and liquefied petroleum gas transportation, storage, processing, and marketing services. The Chemicals segment produces and markets petrochemicals and plastics worldwide. The Refining segment refines crude oil and other feedstocks into petroleum products such as gasoline, distillates, and aviation fuels. The Marketing and Specialties segment purchases for resale and markets refined petroleum products such as base oils and lubricants, and power generation operations. The Renewable Fuels segment processes renewable feedstocks into renewable products at the Rodeo Renewable Energy Complex (Rodeo Complex) and at Humber Refinery. The company was founded in 1875 and is headquartered in Houston, TX.

Phillips 66

Phillips 66 is currently trending as investors weigh activist interest from Elliott Investment Management, which has pushed for operational changes and a potential midstream business spinoff to unlock shareholder value. Community sentiment remains split between excitement over the activist-driven catalyst and concerns regarding the stock's recent price volatility and exposure to fluctuating energy market dynamics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

<ul class="summary-bullets"><li>The Gilead-Tubulis deal is aimed at expanding Gilead’s ADC capabilities by adding Tubulis’s assets that include its lead asset TUB-040.</li><li>According to Leerink analyst Andrew Berens, this acquisition serves as further validation of the antibody-drug conjugate space including Sutro Biopharma.&nbsp;</li><li>Leerink believes Sutro represents a similar set-up as Tubulis, although earlier in clinical development and technological validation.</li></ul><p>Gilead Sciences, Inc. (GILD) said on Tuesday that it has entered into a definitive agreement to acquire a private German clinical-stage biotechnology company, Tubulis GmbH, a move that investment bank Leerink believes should be a tailwind for other antibody-drug conjugate (ADC) platform companies like Sutro Biopharma.</p><p>STRO shares rose 7% at the time of writing while GILD fell 1%.</p><h2 class="st-heading-2">Gilead-Tubulis Agreement Terms</h2><p>Under the terms of the deal, Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash consideration, and up to $1.85 billion in contingent milestone payments.</p><p>The move is aimed at expanding Gilead’s Antibody-drug conjugates capabilities by adding Tubulis’s assets, including its lead asset TUB-040 which is in development to treat certain ovarian cancer and non-small cell lung cancer patients.</p><p>The transaction is expected to close in the second quarter of 2026, Gilead said.</p><p>ADCs are targeted biopharmaceutical cancer treatments that deliver potent cancer drugs directly to cancer cells while minimizing healthy tissue damage.</p><h2 class="st-heading-2">Leerink Weighs In</h2><p>According to Leerink analyst Andrew Berens, this acquisition serves as further validation of the ADC space and should be a tailwind for other ADC platform companies ,including Sutro Biopharma (STRO), as well as Immunome (IMNM) and Zymeworks (ZYME). This deal underscores the strategic value of an ADC discovery platform anchored to a lead asset to large pharma, Berens said.</p><p>However, while there are a number of similarities between Tubulis' platform and portfolio and that of Sutro, it is possible the acquisition price may have been supported by potential expansion of the Tubulis chemistry and technology beyond oncology and into inflammation and virology, Leerink said, as per TheFly. Leerink believes Sutro represents a similar set-up, although earlier in clinical development and technological validation.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around GILD stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume &nbsp;stayed at ‘high’ levels.</p><p>Meanwhile, sentiment around STRO stock remained ‘bullish,’ coupled with ‘low’ message volume.</p><p>While <a href="https://stocktwits.com/symbol/GILD">GILD shares</a> have risen 31% this year, <a href="https://stocktwits.com/symbol/STRO">STRO stock</a> has nearly quadrupled.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-launches-higher-dose-of-wegovy-injection-across-us/cZJJyAuRIpU">Novo Nordisk Launches Higher Dose Of Wegovy Injection Across US — Retail Thinks Stock Is ‘Terribly Undervalued’</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Gilead-Tubulis $5B Deal Gives STRO Stock A Boost — Here’s Why

Gilead said earlier on Tuesday that it will acquire Tubulis for up to $5 billion. 

Equity

Gilead said earlier on Tuesday that it will acquire Tubulis for up to $5 billion. 



Sutro Biopharma (NASDAQ:STRO) Coverage Initiated by Analysts at Leerink Partners

Leerink Partners initiated coverage on shares of Sutro Biopharma in a report on Tuesday. They set an "outperform" rating and a $38.00 price objective for the company...

Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised Sutro Biopharma from a "sell" rating to a "hold" rating in a report on Saturday...

HC Wainwright Lowers Earnings Estimates for Sutro Biopharma

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for Sutro Biopharma in a report issued on Tuesday, March 24th. HC...

Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Sutro Biopharma (NASDAQ:STRO) Stock Price

Deutsche Bank Aktiengesellschaft upped their target price on shares of Sutro Biopharma from $51.00 to $55.00 and gave the stock a "buy" rating in a research report on Wednesday...

HC Wainwright Predicts Sutro Biopharma FY2030 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Investment analysts at HC Wainwright issued their FY2030 EPS estimates for Sutro Biopharma in a report issued on Tuesday, March 24th. HC Wainwright...

Sutro Biopharma (NASDAQ:STRO) Raised to "Overweight" at Wells Fargo & Company

Wells Fargo & Company upgraded Sutro Biopharma from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $8.00 to $27.00 in a research note on Tuesday...

Sutro Biopharma (NASDAQ:STRO) Raised to Buy at HC Wainwright

HC Wainwright raised Sutro Biopharma from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $10.00 to $28.00 in a research report on Tuesday...

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

STRO
Sutro Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest STRO News

STROSutro Biopharma Inc